Prostate cancer-specific survival differences in patients treated by radical prostatectomy versus curative radiotherapy

被引:13
|
作者
DeGroot, Julie M. [1 ]
Brundage, Michael D. [1 ]
Lam, Miu [2 ]
Rohland, Susan L. [1 ]
Heaton, Jeremy [3 ]
Mackillop, William J. [1 ]
Siemens, D. Robert [3 ]
Groome, Patti A. [1 ]
机构
[1] Queens Univ, Canc Res Inst, Canc Care & Epidemiol, Kingston, ON, Canada
[2] Queens Univ, Dept Community Hlth & Epidemiol, Kingston, ON, Canada
[3] Queens Univ, Dept Urol, Kingston, ON, Canada
来源
关键词
EXTERNAL-BEAM RADIOTHERAPY; PROPENSITY SCORE METHODS; ILLNESS RATING-SCALE; CASE-COHORT; RADIATION-THERAPY; SINGLE-INSTITUTION; REGRESSION-MODELS; ANTIGEN ERA; FOLLOW-UP; DEATH;
D O I
10.5489/cuaj.11294
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: We compared the cause-specific survival of patients who received radiotherapy to those who received surgery for cure of their prostate cancer using a number of design and analytic steps to mitigate confounding by indication. Methods: This was a case-cohort study of 2213 patients in the Ontario Cancer Registry diagnosed between 1990 and 1998 who were either treatment candidates or received curative radiotherapy or surgery. Cases included patients who died of prostate cancer within 10 years. The study population was restricted to those who were candidates for either treatment (radiotherapy or surgery) based on disease severity (low and intermediate risk using the Genitourinary Radiation Oncologists of Canada risk groups). The median follow-up was 51 months. Cause-specific survival was analyzed using Cox-proportional hazards regression with case-cohort variance adjustment. Results from intent-to-treat analyses were compared to results by treatment received. Results: Adjusted hazard ratios for risk of prostate cancer death for radiotherapy compared to surgery for the entire study population were 1.62 (95% CI 1.00-2.61) and 2.02 (1.19-3.43) analyzing by intent-to-treat and treatment received, respectively. Intent-to-treat hazard ratios for the low-and intermediate-risk groups were 0.87 (0.28-2.76) and 1.57 (0.95-2.61), respectively. Conclusion: Overall results were driven by the finding in the intermediate-risk group, which indicated that radiotherapy was not as effective as surgery in this group. Confirmation was needed with special attention paid to risk stratification and the impact of more contemporary delivery of these treatment options.
引用
收藏
页码:E299 / E305
页数:7
相关论文
共 50 条
  • [31] NADiA ProsVue Prostate-specific Antigen Slope, CAPRA-S, and Prostate Cancer-specific Survival After Radical Prostatectomy
    Moul, Judd W.
    Sarno, Mark J.
    McDermed, Jonathan E.
    Triebell, Melissa T.
    Reynolds, Mark A.
    UROLOGY, 2014, 84 (06) : 1427 - 1432
  • [32] Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era
    Isbarn, Hendrik
    Wanner, Manuela
    Salomon, Georg
    Steuber, Thomas
    Schlomm, Thorsten
    Koellermann, Jens
    Sauter, Guido
    Haese, Alexander
    Heinzer, Hans
    Huland, Hartwig
    Graefen, Markus
    BJU INTERNATIONAL, 2010, 106 (01) : 37 - 43
  • [33] Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients
    Benedikt Hoeh
    Jan L. Hohenhorst
    Rocco Flammia
    Benedikt Horlemann
    Gabriele Sorce
    Francesco Chierigo
    Zhe Tian
    Fred Saad
    Markus Graefen
    Michele Gallucci
    Alberto Briganti
    Carlo Terrone
    Shahrokh F. Shariat
    Luis A. Kluth
    Andreas Becker
    Felix K. H. Chun
    Pierre I. Karakiewicz
    International Urology and Nephrology, 2022, 54 : 81 - 87
  • [34] Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy
    Mirtti, Tuomas
    Leiby, Benjamin E.
    Abdulghani, Junaid
    Aaltonen, Elina
    Pavela, Miia
    Mamtani, Anita
    Alanen, Kalle
    Egevad, Lars
    Granfors, Torvald
    Josefsson, Andreas
    Stattin, Par
    Bergh, Anders
    Nevalainen, Marja T.
    HUMAN PATHOLOGY, 2013, 44 (03) : 310 - 319
  • [35] Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients
    Hoeh, Benedikt
    Hohenhorst, Jan L.
    Flammia, Rocco
    Horlemann, Benedikt
    Sorce, Gabriele
    Chierigo, Francesco
    Tian, Zhe
    Saad, Fred
    Graefen, Markus
    Gallucci, Michele
    Briganti, Alberto
    Terrone, Carlo
    Shariat, Shahrokh F.
    Kluth, Luis A.
    Becker, Andreas
    Chun, Felix K. H.
    Karakiewicz, Pierre, I
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (01) : 81 - 87
  • [36] Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy
    Peng, Luke C.
    Narang, Amol K.
    Gergis, Carol
    Radwan, Noura A.
    Han, Peijin
    Marciscano, Ariel E.
    Robertson, Scott P.
    He, Pei
    Trieu, Janson
    Ram, Ashwin N.
    McNutt, Todd R.
    Griffith, Emily
    DeWeese, Theodore A.
    Honig, Stephanie
    Singh, Harleen
    Greco, Stephen C.
    Tran, Phuoc T.
    Deville, Curtiland
    DeWeese, Theodore L.
    Song, Daniel Y.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (06) : 309.e7 - 309.e14
  • [37] OVERALL AND CANCER-SPECIFIC SURVIVAL OF HIGH-RISK PROSTATE CANCER - IMPACT OF ADJUVANT THERAPY AFTER RADICAL PROSTATECTOMY
    Ganev, Tosho
    JOURNAL OF IMAB, 2023, 29 (04): : 5188 - 5191
  • [38] Salvage radiotherapy in patients with persisting prostate-specific antigen after radical prostatectomy for prostate cancer
    Bottke, D
    Wiegel, T
    Höcht, S
    Müller, M
    Schostak, M
    Hinkelbein, W
    ONCOLOGY, 2003, 65 : 18 - 23
  • [39] HAZARD OF PROSTATE CANCER-SPECIFIC MORTALITY OVER TIME FOLLOWING RADICAL PROSTATECTOMY
    Shikanov, Sergey
    Dignam, James J.
    Eggener, Scott E.
    JOURNAL OF UROLOGY, 2010, 183 (04): : E53 - E53
  • [40] Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy
    Zhou, P
    Chen, MH
    McLeod, D
    Carroll, PR
    Moul, JW
    D'Amico, AV
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 6992 - 6998